Food and Drug Administration

Pulmonary-Allergy Drugs Advisory Committee

September 5, 2003



The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

ARIFLO® (cilomilast) Tablets, 15 mg, Dr. David Wheadon, MD, GlaxoSmithKline (HTM) (PPT)

SB 207499 (Ariflo®, cilomilast) GlaxoSmithKline New Drug Application 21-573, FDA (HTM) (PPT)